Equities analysts forecast that Intec Pharma Ltd (NASDAQ:NTEC) will announce earnings of ($0.19) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Intec Pharma’s earnings. Intec Pharma reported earnings of ($0.32) per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 40.6%. The firm is expected to report its next quarterly earnings report on Friday, April 6th.
On average, analysts expect that Intec Pharma will report full-year earnings of ($1.35) per share for the current financial year. For the next fiscal year, analysts anticipate that the company will post earnings of ($0.89) per share. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Intec Pharma.
Intec Pharma (NASDAQ:NTEC) last released its earnings results on Wednesday, November 15th. The biotechnology company reported ($0.40) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.34) by ($0.06).
Intec Pharma (NTEC) opened at $5.80 on Tuesday. Intec Pharma has a 12 month low of $4.20 and a 12 month high of $9.80.
Several hedge funds and other institutional investors have recently made changes to their positions in NTEC. Caxton Corp bought a new stake in shares of Intec Pharma in the 3rd quarter valued at approximately $681,000. Pura Vida Investments LLC bought a new stake in shares of Intec Pharma in the 3rd quarter valued at approximately $895,000. Finally, Sectoral Asset Management Inc bought a new stake in shares of Intec Pharma in the 3rd quarter valued at approximately $3,177,000. 40.16% of the stock is owned by institutional investors and hedge funds.
WARNING: This article was first posted by Daily Political and is owned by of Daily Political. If you are reading this article on another publication, it was stolen and reposted in violation of US & international copyright and trademark laws. The original version of this article can be accessed at https://www.dailypolitical.com/2018/02/13/1760112.html.
Intec Pharma Company Profile
Intec Pharma Ltd is an Israel-based drug development company. It is a development stage biopharmaceutical company that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Intec Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma and related companies with MarketBeat.com's FREE daily email newsletter.